In further studies in the general population or in women undergoing a somatic BRCA1/2 test (e.g., for theranostic purposes related to PARP-inhibitor use) regardless of currently used genetic criteria, frequency data for VEO-BC and VEO-OC could be extracted, which would put our results into perspective [80]. This evidence concerns the gene BRCA1 and breast cancer.